---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-005024"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:32:05.382441+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences terminates license agreement with Indiana University for HBV program

## Summary
- On January 11, 2024, Assembly Biosciences notified IURTC of termination of exclusive license for HBV patents including vebicorvir (VBR).
- Termination effective April 11, 2024, 90 days after notice; VBR development was discontinued in July 2022.
- Aggregate milestone payments under the license were $0.8 million; royalties ranged from 0.5% to 1.75% on net sales.
- Annual diligence maintenance fees of $0.1 million were paid, creditable against milestone payments.
- Next-generation capsid assembly modulators (CAMs) were internally discovered and not covered by the terminated license.

## SEC filing metadata
- accession: 0000950170-24-005024
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024005024/0000950170-24-005024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024005024/asmb-20240111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-005024
- JSON: https://secwatch.observer/filing/0000950170-24-005024.json
- Plain text: https://secwatch.observer/filing/0000950170-24-005024.txt

## Key facts
- Material Agreements
  ASSEMBLY BIOSCIENCES, INC. terminated Exclusive License Agreement with Indiana University Research and Technology Corporation (effective 2024-01-11).
  - Action: termination
  - Agreement: license
  - Counterparty: Indiana University Research and Technology Corporation
  - Effective: 2024-01-11
  source text: On January 11, 2024, Assembly Biosciences, Inc. (the "Company") notified the Indiana University Innovation and Commercialization Office that the Company has decided to terminate the Exclusive License Agreement dated September 3, 2023 by and between Indiana University Research and Technology Corporation ("IURTC") and Assembly Pharmaceuticals, Inc., the Company's predecessor (the "License Agreement"), as amended by Amendment No. 1 to the License Agreement dated February 28, 2017 and Amendment No. 2 to the License Agreement dated July 10, 2020.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017024005024/0000950170-24-005024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.